Research progress in dynamic monitoring of lung cancer immunotherapy
10.3760/cma.j.issn.1001-4497.2018.10.020
- VernacularTitle:肺癌免疫治疗动态监测标志物的研究进展
- Author:
Juan ZHOU
1
;
Lei XI
;
Sha ZHAO
;
Chunxia SU
Author Information
1. 200433,同济大学附属上海市肺科医院肿瘤内科
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2018;34(10):636-640
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the application of immune checkpoint blockades has brought dramatical revolution to the treatment of malignant tumors,which not only significantly increase the clinical benefits of partial advanced lung cancer,but also gradually change the landscape of available treatment options for patients with local advanced and early-staged lung cancer.But problems of immunotherapy about efficacy and safety follows.It is urgent to find dynamic biomarkers to identify the patients who are most likely to benefit from immunotherapy and to monitor tumor-specific immune responses.Several dynamic biomarkers have been identified,we will review some of lung cancer-related biomarkers,such as PD-L1 、TMB 、ctDNA 、TILs and peripheral blood biomarkers.
